Literature DB >> 10932270

"Preclinical" AD revisited: neuropathology of cognitively normal older adults.

F A Schmitt1, D G Davis, D R Wekstein, C D Smith, J W Ashford, W R Markesbery.   

Abstract

OBJECTIVE: To classify neuropathologic alterations in the brains of nondemented older adults using current sets of criteria for AD.
BACKGROUND: AD neuropathologic alterations are found in the brains of some nondemented elderly subjects and suggest the possibility of presymptomatic AD. Three sets of guidelines have been developed to classify AD using senile plaques, neuritic plaques, and neurofibrillary tangles (NFT).
METHODS: Neuropathologic changes in 59 older adults followed longitudinally with a standard battery of mental status measures were investigated using Khachaturian, Consortium to Establish a Registry for Alzheimer's Disease (CERAD), and National Institute on Aging-Reagan Institute (NIA-RI) guidelines. AD neuropathologic markers were evaluated in neocortical and allocortical regions. Cases were categorized as neuropathologically "normal" or "AD-like" and compared for possible mental status differences.
RESULTS: Between 11 and 49% of cases met one or more of the three classifications of AD. With adjustments for multiple comparisons, only NFT in hippocampal CA1 region were associated with autopsy age, suggesting that this may represent a pathologic process associated with normal brain aging. Using the NIA-RI guidelines, subjects in the AD-like group performed less well on the immediate paragraph recall and word-list delayed recall than their counterparts who did not meet these guidelines.
CONCLUSIONS: These data indicate that the prevalence of "preclinical" AD in our population is relatively low based on the NIA-RI classification. Although many subjects had AD-like changes based on CERAD and Khachaturian guidelines, they exhibited no differences in mental performance, suggesting that the aging brain may be able to withstand such structural changes without meaningful impact on mental functioning.

Entities:  

Mesh:

Year:  2000        PMID: 10932270     DOI: 10.1212/wnl.55.3.370

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  159 in total

1.  BACE2 expression increases in human neurodegenerative disease.

Authors:  Christopher J Holler; Robin L Webb; Ashley L Laux; Tina L Beckett; Dana M Niedowicz; Rachel R Ahmed; Yinxing Liu; Christopher R Simmons; Amy L S Dowling; Angela Spinelli; Moshe Khurgel; Steven Estus; Elizabeth Head; Louis B Hersh; M Paul Murphy
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

Review 2.  Changes in cognition.

Authors:  Marilyn S Albert
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

3.  Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses.

Authors:  Eric M Blalock; James W Geddes; Kuey Chu Chen; Nada M Porter; William R Markesbery; Philip W Landfield
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-09       Impact factor: 11.205

4.  National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease.

Authors:  Bradley T Hyman; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Maria C Carrillo; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; Bill Thies; John Q Trojanowski; Harry V Vinters; Thomas J Montine
Journal:  Alzheimers Dement       Date:  2012-01       Impact factor: 21.566

5.  Lessons in the study of Alzheimer's disease: a tribute to Dr. William R. Markesbery.

Authors:  Annadora J Bruce-Keller; Jeffrey N Keller
Journal:  Neuromolecular Med       Date:  2010-07-17       Impact factor: 3.843

6.  Factors associated with resistance to dementia despite high Alzheimer disease pathology.

Authors:  D Erten-Lyons; R L Woltjer; H Dodge; R Nixon; R Vorobik; J F Calvert; M Leahy; T Montine; J Kaye
Journal:  Neurology       Date:  2009-01-27       Impact factor: 9.910

7.  Single-Base Resolution Mapping of 5-Hydroxymethylcytosine Modifications in Hippocampus of Alzheimer's Disease Subjects.

Authors:  Elizabeth M Ellison; Melissa A Bradley-Whitman; Mark A Lovell
Journal:  J Mol Neurosci       Date:  2017-09-02       Impact factor: 3.444

Review 8.  Challenges of multimorbidity of the aging brain: a critical update.

Authors:  Kurt A Jellinger; Johannes Attems
Journal:  J Neural Transm (Vienna)       Date:  2014-08-05       Impact factor: 3.575

9.  Resilience of precuneus neurotrophic signaling pathways despite amyloid pathology in prodromal Alzheimer's disease.

Authors:  Sylvia E Perez; Bin He; Muhammad Nadeem; Joanne Wuu; Stephen W Scheff; Eric E Abrahamson; Milos D Ikonomovic; Elliott J Mufson
Journal:  Biol Psychiatry       Date:  2014-01-11       Impact factor: 13.382

10.  Hippocampal proNGF signaling pathways and β-amyloid levels in mild cognitive impairment and Alzheimer disease.

Authors:  Elliott J Mufson; Bin He; Muhammad Nadeem; Sylvia E Perez; Scott E Counts; Sue Leurgans; Jason Fritz; James Lah; Stephen D Ginsberg; Joanne Wuu; Stephen W Scheff
Journal:  J Neuropathol Exp Neurol       Date:  2012-11       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.